<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927221</url>
  </required_header>
  <id_info>
    <org_study_id>JYD0102</org_study_id>
    <nct_id>NCT04927221</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DC739 Multiple-Dose in Hypercholesterolemic Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou JOYO Pharma Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou JOYO Pharma Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      DC739 after multiple-dose oral administration, to explore the clinical effective dose, and to&#xD;
      initially explore the efficacy and safety in hypercholesterolemia subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Totally about 30-50 qualified subjects were assigned to one of the following dose&#xD;
      groups：20mg, 40mg, 60mg, 80mg, 120 mg (60mg and 120mg is the optional dose group). Each of&#xD;
      the dose groups will include 10 subjects (8 for DC739 and 2 for placebo).&#xD;
&#xD;
      Subjects will be admitted for treatment on day -1 and receive the first dose of study drug or&#xD;
      placebo on day 1 and then treat for 28 days. Subjects from different dose groups were&#xD;
      enrolled in turn, the next dose group is conducted on the premise that the D15 safety&#xD;
      evaluation was completed after the administration of the previous dose group with the result&#xD;
      was tolerance.&#xD;
&#xD;
      Blood samples will be collected on day 1 for 48 hours and day 28 for 72 hours after&#xD;
      administration for pharmacokinetic data analysis. Blood lipid will be collected for&#xD;
      effectiveness evaluation. PCSK9 and ANGPTL3, Urine and feces were collected for explore&#xD;
      analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of 5 groups in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant, Investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>tolerability evaluation</measure>
    <time_frame>From informed consent until Day 42.</time_frame>
    <description>12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>From informed consent until Day 42.</time_frame>
    <description>adverse events (AE/SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic evaluation</measure>
    <time_frame>From informed consent until Day 31.</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effective evaluation</measure>
    <time_frame>From informed consent until Day 29.</time_frame>
    <description>LDL-C</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>DC371739 20mg Dose MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administered DC371739 tablets QD afer meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DC371739 Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DC371739 Tablets</intervention_name>
    <description>Participants received one of 5 dose levels of DC371739 administered as single oral doses.</description>
    <arm_group_label>DC371739 20mg Dose MAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally administered as comparison</description>
    <arm_group_label>DC371739 Placebo MAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 to 65 years (inclusive 18 and 65);&#xD;
&#xD;
          -  Body mass index of 18 to 32 kg/m2(inclusive);&#xD;
&#xD;
          -  Hypercholesterolemia subjects with LDL-C≥2.6mmol/L(100mg/dL);&#xD;
&#xD;
          -  Male or female subjects who had no immediate plans to have children, the serum&#xD;
             pregnancy test of women was negative at the time of screening, and agreed to use&#xD;
             strict contraceptive measures throughout the study period and up to 6 months after the&#xD;
             last dose;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECG confirmed that the QT interval was prolonged &gt; 450ms (QT interval corrected for&#xD;
             heart rate by Bazetts formula [QTCB]);&#xD;
&#xD;
          -  Use of statins (lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin,&#xD;
             atorvastatin, cerivastatin, rosuvastatin, pitavastatin, etc.) , ezetimibe, Xuezhikan,&#xD;
             and other lipid-lowering treatment within 2 months prior to screening; use of PCSK9&#xD;
             monoclonal antibodies , fibric acid drugs (such as fenofibrate, gemfibrozil) and&#xD;
             probucol within 3 months prior to screening;&#xD;
&#xD;
          -  Use of warfarin, systemic steroids, cyclosporine, or other immunosuppressive therapy&#xD;
             within months prior to screening;&#xD;
&#xD;
          -  Subjects with HIV-AB , HBsAg, ANTI-TP , HCV-AB positive;&#xD;
&#xD;
          -  A history of prescription drug abuse and illicit drug abuse within 6 months prior to&#xD;
             screening;&#xD;
&#xD;
          -  A history of alcohol abuse within 6 months prior to screening;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ding yan hua, MD</last_name>
    <phone>0431-88782291</phone>
    <email>dingyanhua2003@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xu jun cai, Master</last_name>
    <phone>8602161553050</phone>
    <email>jcxu@joyopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Ji Lin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao li yuan, Master</last_name>
      <phone>0431-88782013</phone>
      <email>kjkzhaoliyuan@126.com</email>
    </contact>
    <investigator>
      <last_name>Ding yanhua, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

